ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Published Sep 9, 2025

Lawrenceville, NJ, USA— September 9,  2025—ISPORThe Professional Society for Health Economics and Outcomes Research (HEOR) announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

The Summit features plenary sessions, workshops, and breakout discussions on today’s most pressing topics, each tied to the bigger picture of real-world evidence (RWE) including health equity, HTA, value-based healthcare, generative AI, health policy, drug price negotiations, and beyond.

Sessions include:

Plenary 1: Realizing RWE Potential in Asia Pacific: Opportunities, Challenges, and Progress
Monday 29, September 2025  
This plenary session examines the evolving landscape of real-world evidence across the Asia Pacific region, where adoption varies significantly between countries despite growing interest. 

Speakers Include:

  • Moderator: Fei-Yuan Sharon Hsiao, PhD, College of Medicine, National Taiwan University, Taipei, Taiwan
  • Mahendra Kumar Rai, PhD, EVERSANA, Singapore, Singapore
  • Sallie Pearson, PhD, The University of New South Wales, Sydney, Australia
  • Bor-Sheng Ko, PhD, MD, National Taiwan University Hospital, New Taipei City, Taiwan
  • Boxiong Tang, PhD, MD, TZ Health, Collegeville, PA, United States
  • Yoshiaki Uyama, PhD, Pharmaceuticals & Medical Devices Agency (PMDA), Tokyo, Japan

Plenary 2: Building the Future: Advancing Real-World Evidence in Asia Pacific and Beyond Tuesday 30, September This plenary panel explores the future for RWE in HEOR and addresses questions around HEOR and how to optimize the use of RWE.

Speakers Include:

  • Moderator: Paul Scuffham, PhD, Griffith University, Gold Coast, Australia
  • Bruce Crawford, MA, MPH, Vista Health Japan KK, Tokyo, Japan
  •  Jing Wu, PhD, Tianjin University, Tianjin, China
  • Ji-Hye Byun, PhD, Health Insurance Review & Assessment Service, Wonju , Korea
  • Azuana Ramli, PhD, Ministry of Health, Petaling Jaya, Malaysia

ISPOR is recognized globally as the leading professional society for health economics and outcomes research and for its role in improving healthcare decisions. The Summit draws healthcare stakeholders from the region with an interest in HEOR, including researchers and academicians, assessors and regulators, payers and policymakers, the life sciences industry, healthcare providers, and patient engagement organizations.

Additional information on the conference can be found at:
Conference Information | Program | Press | Exhibits & Sponsorship | Registration

###

ABOUT ISPOR
ISPOR—The Professional Society for Health Economics and Outcomes Research
(HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Website
 | LinkedIn  | Twitter (@ispororg)  |  YouTube  |  Facebook  |  Instagram  

 

 

 

 

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×